# AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

> **NCT00410904** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer

## Interventions

- **DRUG:** cediranib maleate
- **DRUG:** pemetrexed disodium

## Key facts

- **NCT ID:** NCT00410904
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2013-07
- **Final completion:** 2014-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410904, "AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00410904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*